Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 12;9(12):4019. doi: 10.3390/jcm9124019

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

The clinical impact for the loss of cyclin dependent kinase inhibitor 2A (CDKN2A) functional activity in pancreatic ductal adenocarcinoma. (a) The genetic alterations and mRNA expression levels of CDKN2A gene in 168 pancreatic ductal adenocarcinoma (PDAC) patients; (b) the correlation between CDKN2A genetic alterations (WT for wildtype; MUT for mutation; LOSS for shallow deletion; and DEEP LOSS for deep deletion) and CDKN2A mRNA expression levels; (c) the correlation between CDKN2A mRNA levels and PDAC patients’ overall survivals; (d) the correlation between CDKN2A genetic alterations (WT; MUT; LOSS; and DEEP LOSS) and PDAC patients’ overall survivals; (e) the correlation between CDKN2A genetic alterations and PDAC patients’ primary therapy outcomes (PD for progressive disease; SD for stable disease; PR for partial remission/response; and CR for complete remission/response); (f) the correlation between CDKN2A genetic alterations (MUT + DEEP LOSS vs. WT + LOSS) and PDAC patients’ overall survivals; (g) the correlation between CDKN2A genetic alterations (MUT + DEEP LOSS vs. WT + LOSS) and PDAC patients’ primary therapy outcomes.